抗结核药所致肝损害与药物代谢酶等基因多态性的关联性研究

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (1): 91-95.

抗结核药所致肝损害与药物代谢酶等基因多态性的关联性研究

刘瑜^1,2, 高瑞¹, 陈昱¹, 陈琳¹, 夏春华¹, 邓国防²

¹南昌大学临床药理研究所/江西省临床药物代谢动力学重点实验室, 南昌 330006,江西;
²江西省胸科医院, 南昌 330006,江西;
³深圳市第三人民医院肺二科, 深圳 518112,广东

收稿日期:2014-04-09 修回日期:2014-08-24 发布日期:2020-07-20
通讯作者: 夏春华,通信作者,男,教授,硕士生导师,主要从事药物代谢动力学及临床药理学研究。Tel:0791-86360654 E-mail:xch720917@163.com邓国防,通信作者,男,主任医师,硕士生导师,主要从事抗结核药物肝损伤机制研究。Tel:13530027001 E-mail:jxxk1035@yeah.net
作者简介:刘瑜,女,硕士研究生,研究方向:临床药学及药代动力学。Tel:13807083660 E-mail:362550422@qq.com
基金资助:
国家自然科学基金(81060275,81160411);江西省青年科学家培养对象(20133BCB23006);江西省自然科学基金(20132BAB205013);江西省科技支撑计划(20132BBG70100)

Study progress on anti-tuberculosis drug-induced liver damage associated with drug-metabolizing enzyme gene polymorphism

LIU Yu^1,2, GAO Rui¹, CHEN Yu¹, CHEN Lin¹, XIA Chun-hua¹, DENG Guo-fang²

¹Clinical Pharmacology Institution, Nanchang University/Jiangxi Key Laboratory of Clinical Pharmacokinetics, Nanchang 330006, Jiangxi, China;
²Jiangxi Chest Hospital, Nanchang 330006, Jiangxi, China;
³ Third People's Hospital of Shenzhen, Shenzhen 518112, Guangdong, China

Received:2014-04-09 Revised:2014-08-24 Published:2020-07-20

摘要/Abstract

摘要： 肺结核是由结核分枝杆菌(MTB)感染引起的慢性传染病,是严重危害人类健康的传染病之一。抗结核药物所致肝损害(anti-tuberculosis drug-induced hepatotoxicity, ATDH)是结核病治疗过程中备受关注的问题。有关ATDH的致病机制尚不完全明确,深入探讨肝损害发生的机制显得尤为重要。抗结核药在体内经各种代谢酶及转运体作用形成毒性较低的产物,而这些酶的基因多态性很可能是影响ATDH的重要因素。本文就相关酶的基因多态性与ATDH致病原因作一概述。

关键词: 抗结核药物所致肝损害, 抗结核药, 药物代谢酶, 转运体, 基因多态性

Abstract: Tuberculosis is a chronic infectious disease caused by mycobacterium and is one of the serious infectious diseases harmful to human health. Anti-tuberculosis drug-induced hepatotoxicity (ATDH) draws more attention in the treatment of tuberculosis recently. It is worthy of summarizing the detailed mechanism about ATDH which is still not clear today. It is known to us that anti-tuberculosis drugs are formed less toxic metabolite in vivo by various metabolic enzymes and transporters, and the polymorphisms of transporters and enzymes are likely to be the important factors associated with ATDH. This paper provides an overview about the correlation between drug metabolic enzymes polymorphisms and ATDH.

Key words: ATDH, anti-tuberculosis drug, drug metabolic enzymes, drug transporters, polymorphism

中图分类号:

R968

刘瑜, 高瑞, 陈昱, 陈琳, 夏春华, 邓国防. 抗结核药所致肝损害与药物代谢酶等基因多态性的关联性研究[J]. 中国临床药理学与治疗学, 2015, 20(1): 91-95.

LIU Yu, GAO Rui, CHEN Yu, CHEN Lin, XIA Chun-hua, DENG Guo-fang. Study progress on anti-tuberculosis drug-induced liver damage associated with drug-metabolizing enzyme gene polymorphism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 91-95.

参考文献

[1] Burman WJ, Reves RR. Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers [J]. Am J Respir Crit Care Med, 2001, 164(7): 1112-1113.
[2] Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis [J]. Am J Respir Crit Care Med, 2003, 167(7): 1472-1477.
[3] Lee SW, Chung LS, Huang HH, et al. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis [J]. Int J Tuberc Lung Dis, 2010, 14(5): 622-626.
[4] Bose PD, Sarma MP, Medhi S, et al. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis [J]. J Gastroenterol Hepatol, 2011, 26(2): 312-318.
[5] Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H: quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury [J]. J Hepatol, 2007, 47(1): 128-134.
[6] Vavricka SR, Van Montfoort J, Ha HR, et al. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver [J]. Hepatology, 2002, 36(1): 164-172.
[7] Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes [J]. Lancet, 2000, 356(9241): 1587-1591.
[8] Ellard GA, Gammon PT. Pharmacokinetics of isoniazid metabolism in man [J]. J Pharmacokinet Biopharm, 1976, 4(2): 83-113.
[9] Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity [J]. Respirology, 2006, 11(6): 699-707.
[10] Morel G, Cossec B, Lambert AM, et al. Evaluation of rat hepatic 2E1 activity in function of age, sex and inducers: choice of an experimental model capable of testing the hepatotoxicity of low molecular weight compounds [J]. Toxicol Lett, 1999, 106(2): 171-180.
[11] 崔金霞, 关巍, 冯喜英. N 乙酰化转移酶 2 基因多态性与异烟肼所致肝损伤研究进展[J]. 中国医疗前沿, 2013, 8(9): 16-18.
[12] Roy PD, Majumder M, Roy B. Pharmacogenomics of anti-TB drugs-related hepatotoxicity [J]. Pharmacogenomics, 2008, 9(3): 311-321.
[13] 郝金奇, 陈怡, 李世明, 等. 尿苷二磷酸葡糖醛酸转移酶1A6基因多态性与抗结核药物致肝损害的相关性[J]. 中国肝脏病杂志, 2011, 19(3): 201-204.
[14] Jamis-Dow CA, Katki AG, Collins JM, et al. Rifampin and rifabutin and their metabolism by human liver esterases [J]. Xenobiotica, 1997, 27(10): 1015-1024.
[15] McCarty MF. ''Iatrogenic Gilbert syndrome''-A strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin [J]. Med Hypotheses, 2007, 69(5): 974-994.
[16] Oelberg DG, Lester R. Cellular mechanisms of cholestasis [J]. Annu Rev Med, 1986, 37(1): 297-318.
[17] Nelson SD, Mitchell JR, Timbrell JA, et al. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat [J]. Science, 1976, 193(4256): 901-903.
[18] Mitchel JR, Jollow DJ, Potter WZ, et al. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione [J]. J Pharmacol Exp Ther, 1973, 187(1): 211-217.
[19] Tsutsumi M, Takada A, Wang JS. Genetic polymorphism of cytochrome P-450 2E1 related to the development of alcoholic liver disease [J]. Gastroenterology, 1994, 107(5): 1430-1435.
[20] Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis [J]. Hepatology, 2003, 37(4): 924-930.
[21] Vuilleurnier N, Rossier MF, Chiappe A, et al. CYP2El genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis [J]. Eur J Clin Phamacol, 2006, 62(6): 423-429.
[22] 王涛, 王巍, 王仲元, 等. 细胞色素P450-2E1基因多态性与抗结核药物性肝损害的相关性[J]. 中华结核和呼吸杂志, 2009, 32(8): 585-587.
[23] 吴雪琼, 朱冬林, 张俊仙,等. 羧酸酯酶基因1多态性鉴定及其与抗结核药物肝毒性相关性研究[J]. 中华内科杂志, 2012, 51(7): 524-530.
[24] Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis [J]. Ann Intern Med, 1976, 84(2): 181-192.
[25] Santos NP, Callegari-Jacques SM, Ribeiro Dos Santos AK, et al. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients [J]. Int J Tuberc Lung Dis, 2013, 17(4): 499-504.
[26] Teixeira RL, Morato RG, Cabello PH, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients [J]. Mem Inst Oswaldo Cruz, 2011, 106(6): 716-724.
[27] Mitchell JR, Thorgeirsson UP, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites [J]. Clin Pharmacol Ther, 1975, 18(1): 70-79.
[28] Du H, Chen X, Fang Y, et al. Slow N-acetyltransferase 2 genotype contributes to antituberculosis drug-induced hepatotoxicity: a meta-analysis [J]. Mol Biol Rep, 2013, 40(5): 3591-3596.
[29] 安慧如, 吴雪琼, 王仲元. N-乙酰基转移酶 2 及谷胱甘肽 S 转移酶 M1 基因多态性与抗结核药物性肝损伤的关系研究[J]. 中国防痨杂志, 2014, 36(1): 14-20.
[30] Possuelo LG, lCastclan JA, deyBrito TC, et a1. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil[J]. Eur J Clin Pharmacol, 2008, 64(7): 673-681.
[31] Higuchi N, Tahara N, Yanagihara K, et al. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity In Japanese patients with tuberculosis [J]. World J Gastroenterol, 2007, 13(45): 6003-6008.
[32] Strang RC, Jones PW, Fryer AA. Glutathione S-transferase: Genetics and role in toxiclogy [J]. 2000, 112-113: 357-363.
[33] Leiro V, Fern'andez-Villar A, Valverde D, et al. Infuence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population [J]. Liver Int, 2008, 28(6): 835-839.
[34] Kim SH, Kim SH, Yoon HJ, et al. GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans [J]. Tuberculosis, 2010, 90(1): 39-43.
[35] Tang KS, Lee CM, Teng HC, el a1. UDP-glucuronosyltransferase 1A7 polymorphisms are associated with liver cirrhosis [J]. Biochem Biophys Res Commun, 2008, 366(3): 643-648.
[36] 郝金奇, 陈冶, 李世明, 等. 尿苷二磷酸葡萄糖醛酸转移酶1A7基因多态性与抗结核药致肝损伤易感性的关系[J]. 中华传染病杂志, 2012, 30(3): 174-178.
[37] Li M, Zhang YZ. Modulation of gene expression in cholesterol-lowering effect of electroacupuncture at Fenglong acupoint (ST40): a cDNA microarray study [J]. Int J Mol Med, 2007, 19(4): 617-629.
[38] Weiner M, Peloquin C, Burman W, et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations [J]. Antimicrob Agents Chemother, 2010, 54(10): 4192-4200.
[39] Fountain FF, Tolley EA, Jacobs AR, et al. Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection [J]. Am J Med Sci, 2009, 337(5): 317-320.
[40] Li LM, Chen L, Deng GH, et al. SLCO1B1*15 haplotype is associated with rifampininduced liver injury [J]. Mol Med Rep, 2012, 6(1): 75-82.